The continuing global pandemic has raised society's awareness of the vital role Clinical Trials and Research and Development play in discovering new drugs and vaccines that address illness and disease.
Unfortunately, it has also created additional challenges Clinical Trial Sponsors face when it comes to patient recruitment. The news that the MHRA are looking to allow the use of Real World Data to supplement UK Clinical data will hopefully accelerate the approval process for safe, efficacious drugs and vaccines.
"Evidence derived from RWD may be more representative of the true effects of a treatment in the community, and more generalisable than data from the standardised setting of a traditional clinical trial," the Agency said. In addition, using RWD in clinical studies "has the potential to increase the speed and to reduce the cost of development programmes." A major advantage of RWD is to reduce the burden of data collection for both patient and healthcare professional. It could result in faster drug approvals or increased feasibility of treatment programmes, with consequent benefits to public health.